Panacea Index Logo

Command Palette

Search for a command to run...

Magnesium: An old player revisited in the context of CKD-MBD.

Clinica chimica acta; international journal of clinical chemistry
February 1, 2020
M V Pendón-Ruiz de Mier et al. (5 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the role of metallic elements like calcium in managing CKD-MBD (chronic kidney disease-mineral and bone disorder).

Results Summary

The abstract suggests that calcium-based P binders are among the strategies studied to mitigate CKD-MBD progression, but the focus shifts to magnesium's potential benefits, with no specific results reported for calcium.

Population

Patients with chronic kidney disease (CKD) and associated mineral and bone disorders (CKD-MBD).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
aluminum-based P binders
decrease
CKD-MBD progression
patients with CKD
-
strategies to avoid, reduce, or slow down CKD-MBD progression
#1
magnesium-based P binders
decrease
CKD-MBD progression
patients with CKD
-
strategies to avoid, reduce, or slow down CKD-MBD progression
#2
calcium-based P binders
decrease
CKD-MBD progression
patients with CKD
-
strategies to avoid, reduce, or slow down CKD-MBD progression
#3
magnesium
decrease
CKD-MBD
patients with CKD
-
has been used to treat CKD-MBD
#4
magnesium supplementation
decrease
vascular calcification
patients with CKD
-
efficacy on vascular calcification
#5
magnesium supplementation
increase
renal function
patients with CKD
-
efficacy on renal function
#6
magnesium supplementation
decrease
bone disorders
patients with CKD
-
efficacy on bone disorders
#7
magnesium
decrease
CKD-MBD
patients with CKD
-
potential beneficial effects in the management of CKD-MBD
#8
Abstract

Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD.

Medical Subject Headings (MeSH)
Chronic Kidney Disease-Mineral and Bone DisorderDietary SupplementsHumansMagnesium
Study Links
Quality Scores
SafetyNot Assessed
Efficacy65/10
Quality75/10
Citation Metrics
Total Citations10
Citations/Year2.0
Relative Citation Ratio0.84
NIH Percentile43.8%
Research Impact Scores
APT Score0.75
Weight Score2.22
Normalized Score0.61
Related Supplements